By Marie Rosenthal, MS
BOSTON—A vaginal ring infused with the antiretroviral drug, dapivirine, is reducing women’s HIV risk by more than 50% in two open-label studies of the device, according to results that were presented at CROI 2018.
Nearly 90% of participants in the open-label the HOPE (HIV Open Label Extension) and DREAM (Dapivirine Ring Extended Access and Monitoring) studies are using the monthly ring at least some of the time, according to the interim analyses of study